COVID-19 study: Patients with mild to no symptoms may have comprised immunity
Asymptomatic COVID-19 patients may have significantly lower levels of immunity against the virus than those who become severely ill, an international study revealed on Thursday.
Very little is known about this group, given that they are far less likely to be tested than those who go on to develop severe symptoms including respiratory problems.
Many patients display relatively minor signs of infection, and a small proportion show no symptoms at all.
Researchers based in China compared two groups of individuals infected with COVID-19 in Chongqing’s Wanzhou district: 37 who showed symptoms versus 37 who did not.
The researchers analysed blood samples from both groups taken a few weeks after recovering and found that just 62.2% of the asymptomatic group had short-term antibodies, compared with 78.4% of symptomatic patients.
After eight weeks of convalescence, antibody presence had fallen in 81.1 percent of asymptomatic patients, compared with 62.2 percent of symptomatic patients.
Moreover, asymptomatic patients were found to have lower levels of 18 pro-anti-inflammatory cell-signalling proteins than the symptomatic group, suggesting a weaker immune response to the novel coronavirus.
Authors of the study said their findings called into question the idea that everyone who has had coronavirus is immune to future infection.
“These data might indicate the risks of using COVID-19 ‘immunity passports’ and support the prolongation of public health interventions, including social distancing, hygiene, isolation of high-risk groups and widespread testing,” they wrote.
Danny Altmann, a spokesman for British Society for Immunology as well as professor of Immunology at Imperial College London, said the research raised a vital question for combatting COVID-19.
“Much immunology data so far has come from analysing the sickest, hospitalised patients, but most people who have been more mildly affected will want to know whether this is likely to have conferred lasting, protective immunity,” he said.